GLP-1 receptor agonist treatment in women with polycystic ovary syndrome - a systematic review and meta-analysis - PubMed
5 days ago
- #Meta-analysis
- #Polycystic ovary syndrome
- #GLP-1 receptor agonists
- GLP-1 receptor agonists (GLP1-RAs) were studied for their effects on weight, metabolic, and reproductive outcomes in women with PCOS.
- A systematic review and meta-analysis included 11 RCTs out of 9654 identified studies.
- GLP1-RAs showed a modest reduction in BMI (-1.38 kg/m²) compared to control groups, with low certainty evidence.
- No significant differences were found in LDL cholesterol and triglycerides, and evidence was insufficient for glucose, insulin, hirsutism, and menstrual regularity.
- No studies assessed quality of life, mental health, or cost-effectiveness outcomes.
- Conclusion: GLP1-RAs may aid short-term weight loss in PCOS with overweight/obesity, but benefits on other outcomes remain uncertain due to low-quality data.